An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis

Expert Opinion on Investigational Drugs

Volumn 23, Issue 9, 2014, Pages 1239-1251

  Obici, Laura ^a   Merlini, Giampaolo ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Anti amyloid agents; Antisense oligonucleotides; Diflunisal; Doxycycline; Epigallocatechin gallate; Kinetics stabilizers; Monoclonal antibodies; Protein misfolding; RNAi; Tafamidis

Indexed keywords

AMYLOID; ANTISENSE OLIGONUCLEOTIDE; CURCUMIN; DIFLUNISAL; DOXYCYCLINE; EPIGALLOCATECHIN GALLATE; PREALBUMIN; SMALL INTERFERING RNA; TAFAMIDIS; NEW DRUG;

DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL AMYLOIDOSIS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOTHERAPY; LIVER TRANSPLANTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FOLDING; PROTEIN SYNTHESIS INHIBITION; REVIEW; ADULT; AMYLOID NEUROPATHIES, FAMILIAL; ANIMAL; CLINICAL TRIAL (TOPIC); ONSET AGE; PATHOPHYSIOLOGY; PROCEDURES;

ADULT; AGE OF ONSET; AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN FOLDING; RNA, SMALL INTERFERING;

EID: 84906048507     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.922541     Document Type: Review

References (103)

1. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013;501(7465):45-51
2. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012;19(4):167-70
3. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011;10(12):1086-97
4. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian perspective. Eur Heart J 2013;34(7):520-8
5. Coelho T, Maurer MS, Suhr OB. THAOS-The Transthyretin Amyloidosis Outcomes Survey: Initial report on clinical manifestations in patients with hereditary and wild-Type transthyretin amyloidosis. Curr Med Res Opin 2013;29(1):63-76
6. Plante-Bordeneuve V, Suhr OB, Maurer MS, et al. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: Design and methodology. Curr Med Res Opin 2013;29(1):77-84
7. Quintas A, Vaz DC, Cardoso I, et al. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001;276(29):27207-13
8. Hammarstrom P, Jiang X, Hurshman AR, et al. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 2002;99(Suppl 4):16427-32
9. Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve 2013;47(2):157-62
10. Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 2004;84(5):545-52
11. Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012;109(24):9629-34
12. Coelho T, Maia LF, Martins Da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology 2012;79(8):785-92
13. Coelho T, Maia LF, Da Silva AM, et al. Long-Term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013;260(11):2802-14
14. Lozeron P, Theaudin M, Mincheva Z, et al. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 2013;20(12):1539-45
15. Merlini G, Plante-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 2013;6(6):1011-20
16. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial. JAMA 2013;310(24):2658-67
17. Liz MA, Mar FM, Franquinho F, Sousa MM. Aboard transthyretin: From transport to cleavage. IUBMB Life 2010;62(6):429-35
18. Fleming CE, Mar FM, Franquinho F, et al. Transthyretin internalization by sensory neurons is megalin mediated and necessary for its neuritogenic activity. J Neurosci 2009;29(10):3220-32
19. Buxbaum JN, Ye Z, Reixach N, et al. Transthyretin protects Alzheimers mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci USA 2008;105(7):2681-6
20. Cascella R, Conti S, Mannini B, et al. Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. Biochim Biophys Acta 2013;1832(12):2302-14
21. Li X, Zhang X, Ladiwala AR, et al. Mechanisms of transthyretin inhibition of beta-Amyloid aggregation in vitro. J Neurosci 2013;33(50):19423-33
22. Palaninathan SK, Mohamedmohaideen NN, Snee WC, et al. Structural insight into pH-induced conformational changes within the native human transthyretin tetramer. J Mol Biol 2008;382(5):1157-67
23. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14(30):3219-30
24. Rowczenio D, Wechalekar A. Mutations in hereditary amyloidosis. 2010. Available from: Www. amyloidosismutations.com [Cited 24 April 2014]
25. Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005;121(1):73-85
26. Saraiva MJ, Magalhaes J, Ferreira N, Almeida MR. Transthyretin deposition in familial amyloidotic polyneuropathy. Curr Med Chem 2012;19(15):2304-11
27. Mangione PP, Porcari R, Gillmore JD, et al. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci USA 2014;111(4):1539-44
28. Bourgault S, Solomon JP, Reixach N, Kelly JW. Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry 2011;50(6):1001-15
29. Noborn F, OCallaghan P, Hermansson E, et al. Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proc Natl Acad Sci USA 2011;108(14):5584-9
30. Sousa MM, Cardoso I, Fernandes R, et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy-Evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001;159(6):1993-2000
31. Reixach N, Deechongkit S, Jiang X, et al. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004;101(9):2817-22
32. Andersson K, Olofsson A, Nielsen EH, et al. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Communun 2002;294(2):309-14
33. Andersson K, Pokrzywa M, Dacklin I, Lundgren E. Inhibition of TTR aggregation-induced cell death-A new role for serum amyloid P component. PLoS One 2013;8(2):e55766
34. Hou X, Aguilar MI, Small DH. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 2007;274(7):1637-50
35. Merlini G, Seldin DC, Gertz MA. Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 2011;29(14):1924-33
36. Obici L, Merlini G. AA amyloidosis: Basic knowledge, unmet needs and future treatments. Swiss Med Wkly 2012;142:w13580
37. Yamashita T, Ando Y, Okamoto S, et al. Long-Term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012;78(9):637-43
38. Benson MD, Smith RA, Hung G, et al. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid 2010;17(2):43-9
39. Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006;33(5):609-18
40. Kurosawa T, Igarashi S, Nishizawa M, Onodera O. Selective silencing of a mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res Commun 2005;337(3):1012-18
41. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369(9):819-29
42. Crooke RM, Graham MJ. Modulation of lipoprotein metabolism by antisense technology: Preclinical drug discovery methodology. Methods Mol Biol 2013;1027:309-24
43. Benson MD, Pandey S, Witchell D, et al. Antisense oligonucleotide therapy for TTR amyloidosis. Amyloid 2011;18(Suppl 1):55
44. Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-Associated polyneuropathy. Amyloid 2012;19(Suppl 1):43-4
45. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299(5607):713-16
46. Baures PW, Oza VB, Peterson SA, Kelly JW. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg Med Chem 1999;7(7):1339-47
47. Johnson SM, Wiseman RL, Sekijima Y, et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on the transthyretin amyloidoses. Acc Chem Res 2005;38(12):911-21
48. Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-Agency-Approved drug. J Mol Biol 2012;421(2-3):185-203
49. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006;13(4):236-49
50. Tojo K, Sekijima Y, Kelly JW, Ikeda S. Diflunisal stabilizes familial amyloid polyneuropathy-Associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 2006;56(4):441-9
51. Purkey HE, Dorrell MI, Kelly JW. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc Natl Acad Sci USA 2001;98(10):5566-71
52. Santanna RO, Braga CA, Polikarpov I, et al. Inhibition of human transthyretin aggregation by non-steroidal antiinflammatory compounds: A structural and thermodynamic analysis. Int J Mol Sci 2013;14(3):5284-311
53. Mairal T, Nieto J, Pinto M, et al. Iodine atoms: A new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS One 2009;4(1):e4124
54. Almeida MR, Gales L, Damas AM, et al. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord 2005;4(5):587-96
55. Gales L, Macedo-Ribeiro S, Arsequell G, et al. Human transthyretin in complex with iododiflunisal: Structural features associated with a potent amyloid inhibitor. Biochem J 2005;388(Pt 2):615-21
56. Connelly S, Choi S, Johnson SM, et al. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol 2010;20(1):54-62
57. Choi S, Reixach N, Connelly S, et al. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. J Am Chem Soc 2010;132(4):1359-70
58. Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-Agency-Approved drug. J Mol Biol 2012;421(2-3):185-203
59. Razavi H, Palaninathan SK, Powers ET, et al Benzoxazoles as transthyretin amyloid fibril inhibitors: Synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl 2003;42(24):2758-61
60. Johnson SM, Connelly S, Wilson IA, Kelly JW. Biochemical and structural evaluation of highly selective 2-Arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem 2008;51(2):260-70
61. Alhamadsheh MM, Connelly S, Cho A, et al. Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med 2011;3(97):97ra81
62. Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-Associated V122I transthyretin. Proc Natl Acad Sci USA 2013;110(24):9992-7
63. Kolstoe SE, Ridha BH, Bellotti V, et al. Molecular dissection of Alzheimers disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci USA 2009;106(18):7619-23
64. Bellotti V, Chiti F. Amyloidogenesis in its biological environment: Challenging a fundamental issue in protein misfolding diseases. Curr Opin Struct Biol 2008;18(6):771-9
65. Almeida MR, Saraiva MJ. Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin. FEBS Lett 2012;586(18):2891-6
66. Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4-iodo-4-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995;92(7):2959-63
67. Gianni L, Bellotti V, Gianni AM, Merlini G. New drug therapy of amyloidoses: Resorption of AL-Type deposits with 4-iodo-4-deoxydoxorubicin. Blood 1995;86(3):855-61
68. Cardoso I, Merlini G, Saraiva MJ. 4 -iodo-4 -Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: Screening for TTR fibril disrupters. FASEB J 2003;17(8):803-9
69. Palha JA, Ballinari D, Amboldi N, et al. 4 -iodo-4 -deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol 2000;156(6):1919-25
70. Stoilova T, Colombo L, Forloni G, et al. A new face for old antibiotics: Tetracyclines in treatment of amyloidoses. J Med Chem 2013;56(15):5987-6006
71. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: Evidence from studies in a FAP transgenic mice model. FASEB J 2006;20(2):234-9
72. Macedo B, Batista AR, Ferreira N, et al. Anti-Apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta 2008;1782(9):517-22
73. Cardoso I, Martins D, Ribeiro T, et al. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: Studies in FAP mouse models. J Transl Med 2010;8:74
74. Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: A phase II study. Amyloid 2012;19(Suppl 1):34-6
75. Giorgetti S, Raimondi S, Pagano K, et al. Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. J Biol Chem 2011;286(3):2121-31
76. Diomede L, Soria C, Romeo M, et al. C. elegans expressing human beta(2)-microglobulin: A novel model for studying the relationship between the molecular assembly and the toxic phenotype. PLoS One 2012;7(12):e52314
77. Montagna G, Cazzulani B, Obici L, et al. Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid 2013;20(3):173-8
78. Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood 2011;118(25):6610-17
79. Bieschke J, Russ J, Friedrich RP, et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 2010;107(17):7710-15
80. Ehrnhoefer DE, Bieschke J, Boeddrich A, et al. EGCG redirects amyloidogenic polypeptides into unstructured, offpathway oligomers. Nat Struct Mol Biol 2008;15(6):558-66
81. Hauber I, Hohenberg H, Holstermann B, et al. The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc Natl Acad Sci USA 2009;106(22):9033-8
82. Lopez Del Amo JM, Fink U, Dasari M, et al. Structural properties of EGCGinduced, nontoxic Alzheimers disease Abeta oligomers. J Mol Biol 2012;421(4-5):517-24
83. Hyung SJ, DeToma AS, Brender JR, et al. Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-Associated amyloid-beta species. Proc Natl Acad Sci USA 2013;110(10):3743-8
84. Palhano FL, Lee J, Grimster NP, Kelly JW. Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J Am Chem Soc 2013;135(20):7503-10
85. Ferreira N, Cardoso I, Domingues MR, et al. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett 2009;583(22):3569-76
86. Miyata M, Sato T, Kugimiya M, et al. The crystal structure of the green tea polyphenol (-)-epigallocatechin gallatetransthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry 2010;49(29):6104-14
87. Ferreira N, Saraiva MJ, Almeida MR. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett 2011;585(15):2424-30
88. Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models. PLoS One 2012;7(1):e29933
89. Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: An observational report. Clin Res Cardiol 2012;101(10):805-13
90. Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? Int J Mol Sci 2011;12(9):5592-603
91. Dube A, Nicolazzo JA, Larson I. Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate. Eur J Pharm Sci 2010;41(2):219-25
92. Mazzanti G, Menniti-Ippolito F, Moro PA, et al. Hepatotoxicity from green tea: A review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009;65(4):331-41
93. Pullakhandam R, Srinivas PN, Nair MK, Reddy GB. Binding and stabilization of transthyretin by curcumin. Arch Biochem Biophys 2009;485(2):115-19
94. Ferreira N, Santos SA, Domingues MR, et al. Dietary curcumin counteracts extracellular transthyretin deposition: Insights on the mechanism of amyloid inhibition. Biochim Biophys Acta 2013;1832(1):39-45
95. Sinha S, Lopes DH, Du Z, et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J Am Chem Soc 2011;133(42):16958-69
96. Attar A, Ripoli C, Riccardi E, et al. Protection of primary neurons and mouse brain from Alzheimers pathology by molecular tweezers. Brain 2012;135(Pt 12):3735-48
97. Prabhudesai S, Sinha S, Attar A, et al. A novel "molecular tweezer" inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics 2012;9(2):464-76
98. Ferreira N, Pereira-Henriques A, Attar A, et al. Molecular tweezers targeting transthyretin amyloidosis. Neurotherapeutics 2014;11(2):450-61
99. Gillmore JD, Tennent GA, Hutchinson WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010;148(5):760-7
100. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468(7320):93-7
101. Coutinho P, Martins Da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho E, Costa P, Falcao De Freitas A, editors. Amyloid and amyloidosis. Excerpta Medica, Amsterdam;1980. p. 88-98
102. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013;8:31
103. National Library of Medicine. ClinicalTrials.gov. 2000. Available from: Http://clinicaltrials.gov/ [Cited 24 April 2014].